May 23, 2019
A slew of new drugs joined the NHI reimbursement price list on May 22, with GlaxoSmithKline’s inhaler COPD treatment Trelegy Ellipta (fluticasone furoate + umeclidinium + vilanterol) making its Japan debut. Meanwhile, Novartis Pharma started taking orders for its CAR-T...read more